Literature DB >> 26303603

Trial Watch: Antisenses working overtime in lipids.

Sali M K Farhan1, Robert A Hegele1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26303603     DOI： 10.1038/nrendo.2015.146

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.

Authors:  Pia R Kamstrup; Anne Tybjærg-Hansen; Børge G Nordestgaard
Journal:  J Am Coll Cardiol       Date:  2013-10-23       Impact factor: 24.094

2.  Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation.

Authors:  Rodrigo Alonso; Eduardo Andres; Nelva Mata; Francisco Fuentes-Jiménez; Lina Badimón; José López-Miranda; Teresa Padró; Ovidio Muñiz; Jose Luis Díaz-Díaz; Marta Mauri; Jose María Ordovás; Pedro Mata
Journal:  J Am Coll Cardiol       Date:  2014-03-13       Impact factor: 24.094

3.  Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.

Authors:  Gregory S Thomas; William C Cromwell; Shariq Ali; Wai Chin; JoAnn D Flaim; Michael Davidson
Journal:  J Am Coll Cardiol       Date:  2013-09-04       Impact factor: 24.094

Review 4.  Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum.

Authors:  Marlys L Koschinsky; Michael B Boffa
Journal:  Endocrinol Metab Clin North Am       Date:  2014-12       Impact factor: 4.741

5.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Authors:  Marc S Sabatine; Robert P Giugliano; Stephen D Wiviott; Frederick J Raal; Dirk J Blom; Jennifer Robinson; Christie M Ballantyne; Ransi Somaratne; Jason Legg; Scott M Wasserman; Robert Scott; Michael J Koren; Evan A Stein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

6.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Authors:  Jennifer G Robinson; Michel Farnier; Michel Krempf; Jean Bergeron; Gérald Luc; Maurizio Averna; Erik S Stroes; Gisle Langslet; Frederick J Raal; Mahfouz El Shahawy; Michael J Koren; Norman E Lepor; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; John J P Kastelein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

7.  Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.

Authors:  Rocco Romagnuolo; Corey A Scipione; Michael B Boffa; Santica M Marcovina; Nabil G Seidah; Marlys L Koschinsky
Journal:  J Biol Chem       Date:  2015-03-16       Impact factor: 5.157

8.  Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.

Authors:  Sotirios Tsimikas; Nicholas J Viney; Steven G Hughes; Walter Singleton; Mark J Graham; Brenda F Baker; Jennifer L Burkey; Qingqing Yang; Santica M Marcovina; Richard S Geary; Rosanne M Crooke; Joseph L Witztum
Journal:  Lancet       Date:  2015-07-22       Impact factor: 79.321

9.  Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

Authors:  Daniel Gaudet; Veronica J Alexander; Brenda F Baker; Diane Brisson; Karine Tremblay; Walter Singleton; Richard S Geary; Steven G Hughes; Nicholas J Viney; Mark J Graham; Rosanne M Crooke; Joseph L Witztum; John D Brunzell; John J P Kastelein
Journal:  N Engl J Med       Date:  2015-07-30       Impact factor: 91.245

10.  Genetic variants associated with Lp(a) lipoprotein level and coronary disease.

Authors:  Robert Clarke; John F Peden; Jemma C Hopewell; Theodosios Kyriakou; Anuj Goel; Simon C Heath; Sarah Parish; Simona Barlera; Maria Grazia Franzosi; Stephan Rust; Derrick Bennett; Angela Silveira; Anders Malarstig; Fiona R Green; Mark Lathrop; Bruna Gigante; Karin Leander; Ulf de Faire; Udo Seedorf; Anders Hamsten; Rory Collins; Hugh Watkins; Martin Farrall
Journal:  N Engl J Med       Date:  2009-12-24       Impact factor: 91.245
  10 in total
  1 in total

Review 1.  Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.

Authors:  Wolfgang Poller; Stefanie Dimmeler; Stephane Heymans; Tanja Zeller; Jan Haas; Mahir Karakas; David-Manuel Leistner; Philipp Jakob; Shinichi Nakagawa; Stefan Blankenberg; Stefan Engelhardt; Thomas Thum; Christian Weber; Benjamin Meder; Roger Hajjar; Ulf Landmesser
Journal:  Eur Heart J       Date:  2018-08-01       Impact factor: 29.983
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.